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Introduction
Non-ischemic dilated cardiomyopathy (DCM) patients on
medical therapy have a high morbidity and mortality. The
use of stem cell therapy in this patient subset has not been
previously reported. Cardiac magnetic resonance (CMR) is
the gold standard modality for quantifying ventricular
function. We sought to evaluate the utility of CMR in
assessing outcomes of stem cell therapy in DCM.
Purpose
To report our experience with the use of CMR in asses-
sing results of intracoronary stem cell therapy in non-
ischemic DCM patients.
Methods
Thirty seven patients with non-ischemic DCM under-
went intracoronary injection of autologous bone marrow
derived mononuclear cells. All patients gave informed
consent for stem cell therapy and CMR studies. Mono-
nuclear cells separated from aspirated bone marrow
were injected into right and left coronary arteries. All
patients had baseline CMR, while 10 underwent follow-
up CMR (1.5 T, Magnetom Avanto, Siemens, Germany).
Short axis cine-CMR was performed from the base to
the apex of left ventricle (slice thickness 6-8 mm, inter-
slice gap 2 mm). Images were analyzed for change in
left ventricular (LV) and right ventricular (RV) ejection
fraction (EF), corresponding ventricular volumes [end-
diastolic (EDV), end-systolic (ESV) and stroke volume
(SV)], and LV mass. Wilcoxon signed rank test was used
to compare pre- and post-CMR results. Mann-Whitney
U test was used to correlate change in functional class
and CMR results
Results
Of the 10 patients [eight males; mean age 48.6 years, range
30-64 yrs)], seven improved by at least 1 functional class,
while three showed no change. Follow-up CMR was per-
formed at 8.5±7.8 months. The LVEF (18.4±13% to 26.3
±19%; p=.007), LVSV (29.9±13.4 ml to 52.8±30 ml;
p=.013), RVEF (17±15.3% to 23.4±16.7%; p=.037) and
RVSV (14.4±11.6 ml to 22.3±13 ml; p=.037) improved
significantly. No significant change was noted for EDV,
ESV or LV mass. Compared to those without functional
improvement, patients with improvement showed greater
f a v o r a b l ec h a n g ei nL V E F ,L V S V ,R V E Fa n dR V S V .T h i s
difference was however, not statistically significant.
Conclusions
CMR is accurate for assessing stem cell therapy out-
comes in non-ischemic DCM. Our early results suggest
that this treatment may be beneficial.
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